Literature DB >> 17393979

Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women.

Sathiyamoorthy Selvarajan1, Ka Yan Wong, Kei Siong Khoo, Boon Huat Bay, Puay Hoon Tan.   

Abstract

AIM: We aimed to investigate the immunohistochemical expression of c-erbB-2 in invasive breast carcinoma in Asian women and its correlations with clinicopathological parameters and nuclear morphometry. Patients were followed up for disease relapse and overall survival, and the data were reviewed in conjunction with c-erbB-2 over-expression.
METHODS: Paraffin sections from 321 invasive breast cancers were immunohistochemically stained with anti-human c-erbB-2 antibody using the streptavidin-biotin technique.
RESULTS: c-erbB-2 was over-expressed in 110 (34.3%) cases, with an inverse correlation with oestrogen receptor (ER) and progesterone receptor (PR) status (p=0.0001) and a positive correlation with histological grade (p=0.017). Nuclear morphometry in 96 cases revealed rounder nuclei in c-erbB-2 negative tumours (p=0.0322) when compared with c-erbB-2 positive tumours. Among c-erbB-2 positive cases, malignant cells of histological grade 3 tumours revealed larger nuclear area and perimeter than grade 1 and 2 cases (p=0.0095, p=0.03, respectively) while increasing tumour size correlated with greater nuclear perimeter (p=0.046). c-erbB-2 positivity was significantly associated with poor survival when all patients were included in the analysis (p=0.0166) and for subsets of node positive, histological grade 1 and 2, and ER positive tumours, and in women aged over 50 years (p=0.0047, p=0.0367, p=0.0092, p=0.0096, respectively).
CONCLUSIONS: c-erbB-2 was independently prognostic when histological grade, nodal and ER status were considered. Our results show that c-erbB-2 over-expression correlates with poor histological grade and negative ER/PR status, and predicts poor overall survival in Asian women with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17393979     DOI: 10.1080/00313020601024060

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  4 in total

1.  Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Authors:  Li Ding; Zijin Zhang; Yan Xu; Yongqiang Zhang
Journal:  Bioengineered       Date:  2017-01-11       Impact factor: 3.269

2.  Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.

Authors:  Ana P Ortiz; Orquídea Frías; Carmen González-Keelan; Erick Suárez; David Capó; Javier Pérez; Fernando Cabanillas; Edna Mora
Journal:  P R Health Sci J       Date:  2010-09       Impact factor: 0.705

Review 3.  The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.

Authors:  Yew Oo Tan; Sehwan Han; Yen-Shen Lu; Cheng-Har Yip; Patrapim Sunpaweravong; Joon Jeong; Priscilla B Caguioa; Shyam Aggarwal; Ee Min Yeoh; Hanlim Moon
Journal:  Cancer       Date:  2010-08-16       Impact factor: 6.860

4.  Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.

Authors:  Lobna Ayadi; Abdelmajid Khabir; Habib Amouri; Sondes Karray; Abdallah Dammak; Mohamed Guermazi; Tahya Boudawara
Journal:  World J Surg Oncol       Date:  2008-10-22       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.